West Pharmaceutical Services reported strong financial results for the third quarter of 2020, with organic sales growth of approximately 18% and a contract manufacturing gross profit margin of 17.9%. The company's balance sheet remains strong, with an increase in operating cash flow of $63 million compared to the same period last year. West is expanding its HVP manufacturing capacity to meet anticipated 2021 COVID-19 vaccine demand, with capex guidance remaining at $170 million to $180 million. The company's sales and earnings per share projections for 2020 are in line with its long-term construct of approximately 6% to 8% organic sales growth and earnings per share expansion. West received FDA clearance for its 20 millimeter Vial2Bag advanced product, and the company remains focused on delivering value to all stakeholders while supporting the healthcare industry in resolving the global pandemic.